GlassScriptPhysician profile
Christian Daniel Ward
NPI 1225423924
$9,438.39
in general payments reported to CMS, 2019-2025
33 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,552 · 2020: $1,195 · 2021: $1,640 · 2022: $1,551 · 2023: $1,056 · 2024: $868 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.00 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,803.47 | 2019-2023 | Otezla |
| Lilly USA, LLC | $821.98 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $716.67 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $680.44 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $618.13 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.56 | 2019-2024 | Jardiance |
| Abbvie INC. | $485.94 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $436.21 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $369.09 | 2019-2023 | Verquvo |
| Vifor Pharma, INC. | $350.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $333.98 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $239.98 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $238.22 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $237.42 | 2023-2024 | Inpefa |
| Arbor Pharmaceuticals, INC. | $191.28 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $171.64 | 2020-2025 | Camzyos |
| Allergan, INC. | $157.57 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.00 | 2022 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2019 | |
| Geron Corporation | $124.99 | 2025 | Rytelo |
| Impulse Dynamics (USA) INC. | $120.98 | 2022 | |
| Pfizer INC. | $119.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $98.13 | 2023 | Arexvy |
| Biohaven Pharmaceuticals, INC. | $95.46 | 2021 | |
| Amarin Pharma, INC. | $57.48 | 2021 | |
| Lundbeck LLC | $53.10 | 2019 | |
| Currax Pharmaceuticals LLC | $28.88 | 2021 | |
| Astellas Pharma US INC | $24.81 | 2020 | |
| Scilex Pharmaceuticals INC. | $21.57 | 2020 | |
| Abbott Laboratories | $19.93 | 2022 | |
| Bausch Health US, LLC | $18.25 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.19 | 2022 | |
| Seqirus USA INC | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.